ArticleNature communications2024
Elevated mutation rates in multi-azole resistant Aspergillus fumigatus drive rapid evolution of antifungal resistance.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Accelerated mutator phenotype in a clinicalEmerging microbes & infections · 2026Article
- mSphere of Influence: The age of antifungal resistance.mSphere · 2026Article
- A review on fungal pathogens in the One Health framework: connecting plant, animal, and human health.Archives of microbiology · 2026Review
- WHO Critical Priority Fungi: A Comprehensive Review of Antifungal Resistance, Emerging Therapeutic Strategies, and the Potential of Antifungal Peptides.International journal of molecular sciences · 2026Review
- The future of fungal diagnostics: What's next in laboratory testing for invasive fungal infection?Medical mycology · 2026Review
- Fungal DNA damage repair: from model to driver of virulence and AMR.Bioscience reports · 2026Review
- The BRCT domain enhances DNA binding and catalytic efficiency of fungal PARPs.Nature communications · 2026Article
- Article
- Modelling the role of the microbiome in antimicrobial resistance across scales.Nature microbiology · 2026Review
- Temperature duringbioRxiv : the preprint server for biology · 2026Article
- The dual role of azoles: lifesaving antifungals and drivers of resistance - a One Health perspective.Nature communications · 2026Review
- Genotype-Phenotype Relationships in Azole-ResistantJournal of fungi (Basel, Switzerland) · 2026Review
- Evidence that increased azole persistence and stress resistance precede theMicrobiology spectrum · 2026Article
- Aspergillosis: An Update on Epidemiology, Risk Factors, Diagnosis, Susceptibility, and Treatment.Journal of fungi (Basel, Switzerland) · 2026Review
- Empirical Antifungal Treatment of Critically Ⅲ Patients With Influenza-Associated Acute Respiratory Distress Syndrome: A Propensity Score Weighted Observational Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Observational
- Functional and molecular characterization ofJournal of medical microbiology · 2026Article
- Global epidemiology of azole resistance inJAC-antimicrobial resistance · 2026Review
- Review
- Oxidoreductase geneMicrobiology spectrum · 2026Article
- Detection of TR34/L98H pan-azole-resistantFrontiers in fungal biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The environmental use of azole fungicides has led to selective sweeps across multiple loci in the Aspergillus fumigatus genome causing the rapid global expansion of a genetically distinct cluster of resistant genotypes. Isolates within this cluster are also more likely to be resistant to agricultural antifungals with unrelated modes of action. Here we show that this cluster is not only multi-azole resistant but has increased propensity to develop resistance to next generation antifungals because of variants in the DNA mismatch repair system. A variant in msh6-G233A is found almost exclusively within azole resistant isolates harbouring the canonical cyp51A azole resistance allelic variant TR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.